Orchestra BioMed
OBIO
39 hedge funds and large institutions have $121M invested in Orchestra BioMed in 2023 Q4 according to their latest regulatory filings, with 2 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 5 closing their positions.
157% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 7
6% more capital invested
Capital invested by funds: $114M → $121M (+$7.21M)
0.57% more ownership
Funds ownership: 36.64% → 37.2% (+0.57%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
7% less funds holding
Funds holding: 42 → 39 (-3)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$948K |
| 2 |
State Street
Boston,
Massachusetts
|
+$724K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$266K |
| 4 |
Morgan Stanley
New York
|
+$234K |
| 5 |
Charles Schwab
San Francisco,
California
|
+$149K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.09M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$129K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$110K |
| 4 |
New York State Common Retirement Fund
Albany,
New York
|
-$54.1K |
| 5 |
Allspring Global Investments
Charlotte,
North Carolina
|
-$42.8K |
OBIO Hedge Fund Activity: Q4 2023 in Review
39 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q4 2023, worth a combined $121M — up 6.3% from $114M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of OBIO and 2 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 18 added.
The largest buyer was BlackRock, adding an estimated $948K. The largest seller was Citadel Advisors, cutting an estimated $1.09M.
- 39 institutional investors held Orchestra BioMed (OBIO) as of Q4 2023, down from 42 in Q3 2023.
- Funds reported $121M of Orchestra BioMed stock for Q4 2023, up 6.3% quarter-over-quarter.
- 2 funds opened new Orchestra BioMed positions in Q4 2023 and 5 closed out, a net change of -3 holders.
- The largest Orchestra BioMed buyer in Q4 2023 was BlackRock, an estimated $948K added.
- The largest Orchestra BioMed seller in Q4 2023 was Citadel Advisors, an estimated $1.09M sold.
Based on aggregated 13F filings for Q4 2023.